Quantcast

Latest Telik Inc. Stories

2009-08-03 14:14:00

PALO ALTO, Calif., Aug. 3 /PRNewswire-FirstCall/ -- Telik, Inc. (Nasdaq: TELK) today announced that the positive results from a Phase 1 multicenter, dose escalation study of ezatiostat hydrochloride (TELINTRA, TLK199) tablets in patients with Myelodysplastic Syndrome (MDS) have been published in a leading peer reviewed journal, Blood, 25 June 2009; Vol. 113, No. 26, pp. 6533-6540. Positive results from a separate Phase 1-2a study in MDS patients involving an intravenous formulation of...

2009-06-04 20:00:00

PALO ALTO, Calif., June 4 /PRNewswire-FirstCall/ -- Telik, Inc. (Nasdaq: TELK) announced that company management will provide a corporate overview at the Eighth Annual Needham Life Sciences Conference in New York City on Wednesday, June 10, 2009 at 10:30 a.m. Eastern time (7:30 a.m. Pacific time). A live and archived webcast of the presentation will be available on the Telik website, www.telik.com. Telik, Inc. of Palo Alto, CA, is a clinical stage drug development company focused on...

2009-05-31 17:00:00

PALO ALTO, Calif., May 31 /PRNewswire-FirstCall/ -- Telik, Inc. (Nasdaq: TELK) today announced presentation at the 45th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Orlando, Florida, of results from the ASSIST-5 Phase 3 randomized, multinational study of TELCYTA(R) (canfosfamide HCl) in combination with pegylated liposomal doxorubicin (PLD) vs. PLD alone in second-line therapy in platinum refractory or resistant ovarian cancer. Study Design: Patients with...

2009-05-21 15:05:00

PALO ALTO, Calif., May 21 /PRNewswire-FirstCall/ -- Telik, Inc. (Nasdaq: TELK) announced today that the results from the randomized clinical study of canfosfamide (TELCYTA(R), TLK286) in combination with pegylated liposomal doxorubicin (PLD) vs. PLD will be presented at the 45th annual meeting of the American Society of Clinical Oncology (ASCO) which will be held from May 29 to June 2 in Orlando, FL. Details of the presentation are as follows: -- Abstract #5552 - General Poster...

2009-05-07 15:05:00

PALO ALTO, Calif., May 7 /PRNewswire-FirstCall/ -- Telik, Inc. (Nasdaq: TELK) today reported financial results for the first quarter ended March 31, 2009. The net loss for the quarter ended March 31, 2009, was $7.7 million, or $0.14 per share, compared with a net loss of $9.8 million, or $0.19 per share, for the same period in 2008. As of March 31, 2009, cash, cash equivalents, restricted cash and investments totaled $57.3 million, compared with $63.5 million for the quarter ended...

2009-04-28 17:33:00

PALO ALTO, Calif., April 28 /PRNewswire-FirstCall/ -- Telik, Inc. (Nasdaq: TELK) announced results of studies on two of its drug development programs that were presented at the 100th annual meeting of the American Association for Cancer Research (AACR) in Denver, CO. The abstracts can be found on the Telik website, www.telik.com. In vivo Characterization and Mechanism of Action of Orally Active Aurora Kinase/ VEGFR Inhibitors; Abstract # 1764 Aurora kinases are Ser/Thr kinases that play an...

2009-04-14 19:27:00

PALO ALTO, Calif., April 14 /PRNewswire-FirstCall/ -- Telik, Inc. (Nasdaq: TELK) announced today that two abstracts highlighting results from its Research and Development programs will be presented at the 100th annual meeting of the American Association for Cancer Research (AACR) in Denver, CO. Details of the presentations are as follows: In vivo Characterization and Mechanism of Action of Orally Active Aurora Kinase/VEGFR Inhibitors; Sunday, April 19, 2009, 1:00 - 5:00pm; Kinase...

2009-02-26 15:08:00

PALO ALTO, Calif., Feb. 26 /PRNewswire-FirstCall/ -- Telik, Inc. (Nasdaq: TELK) reported a net loss of $0.4 million, or $0.01 per share, for the three months ended December 31, 2008, compared with a net loss of $12.9 million, or $0.25 per share, for the same period in 2007. For the twelve months ended December 31, 2008, Telik reported a net loss of $31.8 million, or $0.60 per share, compared with a net loss of $55.2 million, or $1.05 per share, for the year ended December 31, 2007. The...

2009-02-19 15:03:00

PALO ALTO, Calif., Feb. 19 /PRNewswire-FirstCall/ -- Telik, Inc. (Nasdaq: TELK) announced that its year-end conference call and webcast will be held on Thursday, February 26, 2009 at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) following the release earlier that day of the company's financial results for the fourth quarter and year ended December 31, 2008. The conference call will be accessible via Telik's website at http://www.telik.com or by telephone at 800-288-8974 or...

2009-02-11 16:00:00

PALO ALTO, Calif., Feb. 11 /PRNewswire-FirstCall/ -- Telik, Inc. (Nasdaq: TELK) announced today that it is implementing a reorganization to focus on its most advanced preclinical and clinical drug development programs. The reorganization will enable the company to continue the development of TELINTRA(R) and the two leading preclinical drug candidates: a prodrug cytotoxic, TLK58747, and dual Aurora-VEGFR kinase inhibitor, TLK60404. The restructuring will involve a workforce reduction of...


Word of the Day
jument
  • A beast of burden; also, a beast in general.
'Jument' ultimately comes from the Latin 'jugum,' yoke.
Related